Abivax (ABVX) Assets Average (2022 - 2026)
Abivax (ABVX) posted quarterly Assets Average of $660.4 million for Q1 2026, up 234.47% year-over-year from $197.4 million in Q1 2025, and down 8.44% quarter-over-quarter from $721.2 million in Q4 2025.
Abivax (ABVX) Assets Average (2022 - 2026) Analysis & Trends
Abivax's Assets Average history runs 4 years deep, the most recent figure standing at $660.4 million for Q1 2026.
- In Q1 2026, Assets Average rose 234.47% year-over-year to $660.4 million; the TTM figure through Mar 2026 stood at $660.4 million (up 234.47% YoY), while the FY2025 annual figure was $449.7 million, up 57.48% from the prior year.
- Assets Average for Q1 2026 stood at $660.4 million, down from $721.2 million in the prior quarter.
- The five-year high for Assets Average was $721.2 million in Q4 2025, with the low at $101.0 million in Q4 2022.
- The 4-year median for Assets Average is $214.5 million (2023), against an average of $357.0 million.
- The sharpest annual moves came in 2023 and 2026: Assets Average jumped 112.33% in 2023, then soared 234.47% in 2026.
- Abivax's Assets Average stood at $101.0 million in 2022, then surged by 112.33% to $214.5 million in 2023, then jumped by 236.26% to $721.2 million in 2025, then slipped by 8.44% to $660.4 million in 2026.
- Business Quant data shows ABVX's Assets Average at $660.4 million in Q1 2026, $721.2 million in Q4 2025, and $448.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 660.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 660.38 Mn |
| Dec 31, 2025 | 721.24 Mn |
| Sep 30, 2025 | 448.86 Mn |
| Jun 30, 2025 | 155.51 Mn |
| Mar 31, 2025 | 197.44 Mn |
| Dec 31, 2023 | 214.49 Mn |
| Dec 31, 2022 | 101.01 Mn |